Rho site logo


The Medical Countermeasures Clinical Studies Network (MCM-CSN), funded and managed by the Biomedical Advanced Research and Development Authority (BARDA)Office of the Assistant Secretary for Preparedness and Response (ASPR),US Department of Health and Human Services (DHHS), designs and conducts clinical studies needed to develop medical countermeasures - drugs, vaccines and diagnostic tests - that help protect public health against bioterrorism, pandemic influenza, and other health emergencies.

As one of the five clinical research organizations within the MCM-CSN, Rho will support targeted clinical studies relevant to BARDA's vision to create a nation with the capability to respond quickly and effectively to deliberate, natural, and emerging threats by providing a range of clinical study services that can be used by BARDA and its development partners. Trials will evaluate chemical, biological, radiological, nuclear, pandemic influenza, and emerging infectious disease medical countermeasures. 

Gloria David, PhD, MHSc, is Principal Investigator (PI) for this project.